GENinCode plc (GENI) ORD GBP0.01
- Add to watchlist
- Create an alert
- This stock can be held in a
Business summary
GENinCode Plc is a United Kingdom-based predictive genetics company. The Company is engaged in the risk assessment, prediction, and prevention of cardiovascular disease (CVD). Its tests include Cardio Incode, Lipid Incode, Sudd Incode, Roca Test, Thrombo and Thrombo Incode Reproductive Health. The Company's product portfolio draws on advanced genomic precision testing using polygenic (multiple genes) technology, molecular testing, genotyping, sequencing, and AI bioinformatics to risk assess patient DNA. Its predictive technology provides patients and physicians with global preventative care and treatment strategies. Its products combine genetic and clinical data to risk-assess patients and provide healthcare practitioners with advanced clinical information to evaluate and predict the onset of cardiovascular disease. The Company’s wholly owned subsidiaries include GENinCode S.L.U. and GENinCode U.S. INC.
Contact details
Important dates
General stock information
- EPIC:
- GENI
- ISIN:
- GB00BL97B504
- Market cap:
- £13.71 million
- Shares in issue:
- 176.96 million
- Sector:
- No specific Industry
- Exchange:
- London Stock Exchange
- Currency:
- Sterling pence
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.